Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B

被引:37
作者
Zhang, LX [1 ]
Wang, B [1 ]
机构
[1] Chinese Med Assoc, Beijing Branch, Beijing 100050, Peoples R China
关键词
hepatitis B; glycyrrhizin; Stronger Neo-Minophagen C;
D O I
10.1016/S1386-6346(02)00086-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Stronger Neo-Minophagen C (SNMC) is an intravenous drug with glycyrrhizin as the principal ingredient. The efficacy and safety of SNMC at two doses were evaluated on 194 patients with chronic hepatitis B in nine hospitals in China. They all had serum levels of alanine aminotransferase (ALT) exceeding twice the upper limit of normal ( > 80 IU/1). SNMC daily 100 and 40 ml were given for 4 weeks to the patients randomized into Group A (N = 99) and Group B (N = 95), respectively. Thereafter, all patients received oral glycyrrhizin (GLYCYRON Tab) 9 tablets a day for an additional 4 weeks. Primary end-point was ALT < 1.5 times the upper limit of normal (60 IU/1) at completion of the 8-week therapy, and it was achieved by 73 patients (74%) in Group A and 74 (79%) patients in Group B; normalization of ALT levels ( < 40 IU/1) was accomplished in 58 (58%) and 54 (57%) patients in Groups A and B, respectively. SNMC was withdrawn in four (2%) patients due to mild and reversible side effects. Based on these results, SNMC is safe and efficacious in lowering or normalizing ALT levels in patients with chronic hepatitis B in China, and an induction dose of 40 in] daily is efficient in achieving maximal effects. (C) 2002 Published by Elsevier Science B.V.
引用
收藏
页码:220 / 227
页数:8
相关论文
共 20 条
[1]  
Aso Y., 1977, IGAKUNO AYUMI, V102, P562
[2]   Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy [J].
Chayama, K ;
Suzuki, Y ;
Kobayashi, M ;
Kobayashi, M ;
Tsubota, A ;
Hashimoto, M ;
Miyano, Y ;
Koike, H ;
Kobayashi, M ;
Koida, I ;
Arase, Y ;
Saitoh, S ;
Murashima, N ;
Ikeda, K ;
Kumada, H .
HEPATOLOGY, 1998, 27 (06) :1711-1716
[3]  
HINO K, 1986, KAN TAN SUI, V13, P797
[4]   Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis [J].
Iino, S ;
Tango, T ;
Matsushima, T ;
Toda, G ;
Miyake, K ;
Hino, K ;
Kumada, H ;
Yasuda, K ;
Kuroki, T ;
Hirayama, C ;
Suzuki, H .
HEPATOLOGY RESEARCH, 2001, 19 (01) :31-40
[5]   Medical progress - Hepatitis B virus infection [J].
Lee, WM .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (24) :1733-1745
[6]  
Leung N, 2000, J MED VIROL, V61, P380, DOI 10.1002/1096-9071(200007)61:3&lt
[7]  
380::AID-JMV17&gt
[8]  
3.0.CO
[9]  
2-5
[10]   Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy [J].
Liaw, YF ;
Chien, RN ;
Yeh, CT ;
Tsai, SL ;
Chu, CM .
HEPATOLOGY, 1999, 30 (02) :567-572